Literature DB >> 6242007

Immune derangements in asymptomatic male homosexuals in Israel: a pre-AIDS condition?

Z T Handzel, E Galili-Weisstub, R Burstein, Y Berner, M Pecht, L Netzer, N Trainin, N Barzilai, S Levin, Z Bentwich.   

Abstract

We have described several immune derangements found in a clinically asymptomatic group of 117 male homosexuals (MHS) in Israel. These consisted of a marked decrease in TH and TS cells, decreased NK and allogeneic response, and increased levels of acid labile alpha-interferon and circulating immune complexes (CIC). Most of these alterations were found in approximately 40% of the subjects, with no simple correlation between them. Since Israel is a low incidence area for AIDS and related syndromes, it is suggested that this situation reflects a common situation among asymptomatic MHS in general, although the reasons for these impairments are not clear. This situation may therefore explain susceptibility of the male homosexual for developing AIDS, given the appropriate circumstances, environment, and genetic background.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6242007     DOI: 10.1111/j.1749-6632.1984.tb37183.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Immune impairments and antibodies to HTLVIII/LAV in asymptomatic male homosexuals in Israel: relevance to the risk of acquired immune deficiency syndrome (AIDS).

Authors:  Z Bentwich; C Saxinger; Z Ben-Ishay; R Burstein; Y Berner; M Pecht; N Trainin; S Levin; Z T Handzel
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

2.  Sequential serological studies of homosexual men with and without HIV infection. Epstein-Barr virus activation preceding and following HIV seroconversion.

Authors:  A Schattner; N Hanuka; B Sarov; I Sarov; Z Handzel; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

3.  Serum IgD elevation is an early marker of B cell activation during infection with the human immunodeficiency viruses.

Authors:  H Mizuma; S Zolla-Pazner; S Litwin; W el-Sadr; S Sharpe; B Zehr; S Weiss; W C Saxinger; M Marmor
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.